Welcome to our dedicated page for Wave Life Scienc SEC filings (Ticker: WVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wave Life Sciences Ltd. filings document a clinical-stage biotechnology company developing RNA medicines through the PRISM platform and Nasdaq-listed $0 par value ordinary shares under WVE. Its 8-K reports furnish operating and financial results, Regulation FD corporate presentations and material-event disclosures tied to clinical programs, regulatory communications and pipeline updates for oligonucleotide candidates including WVE-006 and WVE-007.
Proxy and governance filings cover shareholder voting matters, board and governance disclosures, material agreements, capital-structure information and risk factors. The company's formal disclosures also address clinical and regulatory risks, collaboration-related matters, financial condition, and the corporate controls associated with an RNA-medicines development business.
Wave Life Sciences reported much higher cash and a larger loss for 2025 while outlining ambitious RNA programs in obesity, liver and lung disease. Cash and cash equivalents rose to $602.1 million as of December 31, 2025, giving an expected cash runway into Q3 2028.
Full-year 2025 revenue was $42.7 million, down from $108.3 million in 2024, as collaboration revenue declined. Research and development expenses increased to $182.8 million and general and administrative to $75.3 million, driving a net loss of $204.4 million versus a $97.0 million loss in 2024.
The company highlighted WVE-007 for obesity, where a single dose showed fat loss similar to GLP‑1 drugs at three months while preserving lean mass, with data updates and a Phase 2a multidose trial planned in 2026. It also advanced WVE‑006 for alpha‑1 antitrypsin deficiency, achieving total AAT levels above 11 micromolar and dynamic increases during acute phase responses, and plans a 2026 clinical trial application for WVE‑008 in PNPLA3 I148M liver disease.
Wave Life Sciences Ltd. received an updated ownership report from Adage Capital Management, L.P. and principals Robert Atchinson and Phillip Gross. The reporting group states beneficial ownership of 9,786,061 ordinary shares, representing 5.35% of the class as of the event date.
All 9,786,061 shares are reported with shared voting and shared dispositive power, and no shares with sole power. The percentage is based on a total of 182,971,259 ordinary shares outstanding, which combines 167,181,784 shares outstanding as of November 7, 2025 and 15,789,475 shares offered under a December 11, 2025 prospectus. The filers certify the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Wave Life Sciences’ Chief Financial Officer Kyle Moran reported routine equity compensation and a related tax sale. On February 5, 2026, he received 45,625 restricted share units that vest in four equal annual installments from February 8, 2027 through February 8, 2030, and a share option for 273,750 ordinary shares at an exercise price of $12.75 per share, vesting 25% on February 8, 2027 and 6.25% quarterly thereafter until February 8, 2030. Following these grants, he held 137,973 ordinary shares and 273,750 options directly. On February 9, 2026, he sold 3,588 ordinary shares at $13.45 per share to cover taxes triggered by RSU vesting under an automatic sale provision, leaving 134,385 ordinary shares owned directly.
Wave Life Sciences Ltd. insider activity: President and CEO Paul Bolno received 165,000 restricted share units on February 5, 2026, bringing his direct holdings to 286,000 ordinary shares. These RSUs vest in four equal annual installments from February 8, 2027 through February 8, 2030.
On February 9, 2026, he sold 10,480 ordinary shares at $13.45 each solely to cover taxes from RSU vesting, leaving 275,520 shares owned directly. He also received a stock option for 1,000,000 ordinary shares at a $12.75 exercise price, vesting 25% on February 8, 2027 and 6.25% quarterly until February 8, 2030.
Wave Life Sciences (WVE) executive Chris Francis reported equity compensation grants and a small tax-related share sale. On February 5, 2026, he received 38,750 restricted share units that vest in four equal annual installments from February 8, 2027 through February 8, 2030, and a share option for 232,500 ordinary shares at an exercise price of $12.75 per share, vesting 25% on February 8, 2027 and 6.25% quarterly until February 8, 2030. On February 9, 2026, he sold 1,883 ordinary shares at $13.45 per share solely to cover taxes from RSU vesting, leaving 61,867 ordinary shares held directly.
Wave Life Sciences Ltd. executive Chandra Vargeese reported new equity awards and a small share sale. On February 5, 2026, Vargeese acquired 45,625 restricted share units, which vest in four annual 25% installments from February 8, 2027 through February 8, 2030. The same day, Vargeese received a stock option for 273,750 ordinary shares at an exercise price of $12.75, vesting 25% on February 8, 2027 and an additional 6.25% quarterly until February 8, 2030. On February 9, 2026, Vargeese sold 3,228 ordinary shares at $13.45 per share solely to cover taxes related to RSU vesting, as required under the RSU agreement. After these transactions, Vargeese directly held 408,246 ordinary shares and 273,750 options.
Kyle Moran filed a notice of proposed sale for 3,564 ordinary shares of WVE, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ around 02/09/2026, with an aggregate market value of $47,935.80. These shares were acquired via restricted stock unit vesting on 02/08/2026 as equity compensation.
During the prior three months, Kyle Moran sold 210,000 ordinary shares on 12/08/2025 for gross proceeds of $3,102,000.00 and 86,000 ordinary shares on 12/09/2025 for gross proceeds of $1,730,250.00. Ordinary shares outstanding were 187,693,059 at the time of the planned sale.
Chris Francis has filed a notice of proposed share sales under Rule 144 for Wave Life Sciences (symbol WVE). The filing covers 1,870 ordinary shares to be sold through Morgan Stanley Smith Barney LLC on or about 02/09/2026 on NASDAQ, with an aggregate market value of 25,151.50 and 187,693,059 ordinary shares outstanding.
The 1,870 shares were acquired on 02/08/2026 through restricted stock unit vesting from the issuer as equity compensation. In the past three months, Francis has already sold 441,031 ordinary shares on 12/08/2025 for gross proceeds of 6,427,084.96 and 9,375 ordinary shares on 01/02/2026 for 150,260.10.
A shareholder has filed a Rule 144 notice to sell 10,411 ordinary shares. The shares are planned to be sold on the NASDAQ through Morgan Stanley Smith Barney LLC at an aggregate market value of $140,027.95, with 187,693,059 shares outstanding.
The securities to be sold were acquired on 02/08/2026 through the vesting of restricted stock units as equity compensation from the issuer, with payment also dated 02/08/2026. The notice includes a representation that the seller is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
FMR LLC and Abigail P. Johnson report beneficial ownership of 15,020,982.62 shares of Wave Life Sciences Ltd. common stock, representing 8.5% of the class as of December 31, 2025. FMR LLC holds sole voting power over 15,016,629.00 shares and sole dispositive power over 15,020,982.62 shares.
Abigail P. Johnson is reported with sole dispositive power over 15,020,982.62 shares but no voting power. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Wave Life Sciences.